Pathstone Family Office, LLC X4 Pharmaceuticals, Inc Transaction History
Pathstone Family Office, LLC
- $15.6 Billion
- Q3 2023
A detailed history of Pathstone Family Office, LLC transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Pathstone Family Office, LLC holds 12,637 shares of XFOR stock, worth $8,466. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,637Holding current value
$8,466% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding XFOR
# of Institutions
104Shares Held
100MCall Options Held
213KPut Options Held
50.6K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$11.3 Million2.03% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$10 Million0.77% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$7.15 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.44MShares$5.66 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$4.78 Million0.11% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $46M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...